全文获取类型
| 收费全文 | 14268篇 |
| 免费 | 992篇 |
| 国内免费 | 32篇 |
专业分类
| 耳鼻咽喉 | 120篇 |
| 儿科学 | 431篇 |
| 妇产科学 | 508篇 |
| 基础医学 | 2115篇 |
| 口腔科学 | 242篇 |
| 临床医学 | 1806篇 |
| 内科学 | 2500篇 |
| 皮肤病学 | 409篇 |
| 神经病学 | 1369篇 |
| 特种医学 | 272篇 |
| 外科学 | 1283篇 |
| 综合类 | 100篇 |
| 一般理论 | 43篇 |
| 预防医学 | 1601篇 |
| 眼科学 | 237篇 |
| 药学 | 1041篇 |
| 中国医学 | 24篇 |
| 肿瘤学 | 1191篇 |
出版年
| 2024年 | 14篇 |
| 2023年 | 141篇 |
| 2022年 | 329篇 |
| 2021年 | 560篇 |
| 2020年 | 277篇 |
| 2019年 | 494篇 |
| 2018年 | 521篇 |
| 2017年 | 353篇 |
| 2016年 | 458篇 |
| 2015年 | 442篇 |
| 2014年 | 617篇 |
| 2013年 | 779篇 |
| 2012年 | 1116篇 |
| 2011年 | 1190篇 |
| 2010年 | 644篇 |
| 2009年 | 528篇 |
| 2008年 | 885篇 |
| 2007年 | 923篇 |
| 2006年 | 898篇 |
| 2005年 | 830篇 |
| 2004年 | 720篇 |
| 2003年 | 636篇 |
| 2002年 | 614篇 |
| 2001年 | 91篇 |
| 2000年 | 84篇 |
| 1999年 | 87篇 |
| 1998年 | 114篇 |
| 1997年 | 80篇 |
| 1996年 | 73篇 |
| 1995年 | 62篇 |
| 1994年 | 74篇 |
| 1993年 | 51篇 |
| 1992年 | 50篇 |
| 1991年 | 50篇 |
| 1990年 | 34篇 |
| 1989年 | 42篇 |
| 1988年 | 39篇 |
| 1987年 | 20篇 |
| 1986年 | 25篇 |
| 1985年 | 34篇 |
| 1984年 | 33篇 |
| 1983年 | 29篇 |
| 1982年 | 30篇 |
| 1981年 | 36篇 |
| 1980年 | 31篇 |
| 1979年 | 19篇 |
| 1978年 | 19篇 |
| 1977年 | 23篇 |
| 1976年 | 17篇 |
| 1974年 | 16篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
141.
142.
143.
This study tested a brief, Web-based personalized feedback program aimed at reducing alcohol use and alcohol-related consequences among 9th grade students (N = 513). Results indicated no differences between the control group and intervention group on either frequency of drinking or alcohol-related consequences at the 6-month follow-up. Reductions in alcohol use and the associated consequences found at the 3-month follow-up were not sustained across the academic year. Results indicate that brief, Web-based feedback programs may not be sufficient to provide a sustained impact on alcohol use and alcohol-related consequences over time, suggesting either booster sessions or adjunctive interventions, such as parent-based interventions, may be warranted for this age group. 相似文献
144.
145.
146.
147.
148.
Fabián Matías Caro María Laura Alberti Federico Campins Juan Ignacio Enghelmayer Martín Eduardo Fernández Diana Lancellotti Tulio Papucci Javier Adrián Sebastiani Francisco Paulin 《Archivos de bronconeumologia》2019,55(2):75-80
Introduction
Pirfenidone was the first antifibrotic drug approved in Argentina for idiopathic pulmonary fibrosis (IPF). Outcomes in real life may differ from the results of clinical trials. The primary endpoint was to study the tolerance of pirfenidone in real life. Secondary endpoints were to analyze effectiveness and reasons for discontinuation.Materials and methods
Retrospective observational study conducted in four specialized centers in Argentina. We analyzed the medical records of patients with IPF who received pirfenidone between June 2013 and September 2016. Adverse events (AE) and the variables that could influence these results were analyzed. Forced vital capacity (FVC%) parameters were also compared between the pre-pirfenidone and post-pirfenidone periods.Results
Fifty patients were included, 38 (76%) men, with mean age (SD) 67.8 (8.36) years. Mean (SD) exposure to pirfenidone was 645.68 (428.19) days, with a mean daily dose (SD) of 2064.56 mg (301.49). Nineteen AEs in 15 patients (30%) were reported: nausea (14%), asthenia (10%) and skin rash (8%). A total of 18 patients (36%) interrupted treatment, only 1 definitively. The most frequent reason for discontinuation was failure of suppliers to provide the drug (9 subjects; 18%). We compared the evolution of FVC% between the pre-pirfenidone and post-pirfenidone periods, and found a mean (SD) FVC% decline of 4.03% (7.63) pre-pirfenidone and 2.64% (7.1) post-pirfenidone (P=.534).Conclusions
In our study, pirfenidone was well tolerated and associated with a reduction in FVC decline, although without reaching statistical significance. 相似文献149.
150.
Adriana Benavides-Lara María de la Paz Barboza-Arguello Mauricio Gonzlez-Elizondo Marcela Hernndez-deMezerville Helena Brenes-Chacn Melissa Ramírez-Rojas Catalina Ramírez-Hernndez Nereida Arjona-Ortegn Shana Godfred-Cato Diana Valencia Cynthia A. Moore Alejandra Soriano-Fallas 《Emerging infectious diseases》2021,27(2):360